Considerations for the Real-World Management of ARIA From the Aducanumab Phase 3 Studies EMERGE and ENGAGE (P1-1.Virtual)
Richard E. Hughes(University of Michigan), Samantha Budd Haeberlein(Biogen (United States)), Karen Smirnakis(Biogen (United States)), Derk D. Purcell(BioClinica (United States)), Patrick Burkett(Biogen (United States)), Sami Fam(Biogen (United States)), Carmen Castrillo‐Viguera(Biogen (United States)), Kimberly Umans(Biogen (United States)), Jerome Barakos(Sutter Health), Spyridon Chalkias(Institute of Neuroimmunology of the Slovak Academy of Sciences)
Cited by 0
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k